Form 4: Inhibrx Biosciences President Receives Stock Options

Inhibrx Biosciences President David Matly was granted 50,000 stock options as part of a standard equity compensation package.

Summary

• David Matly, President of Inhibrx Biosciences, Inc., was granted 50,000 stock options on April 24, 2026.
• The options have an exercise price of $129.06 per share.
• The options are subject to a four-year vesting schedule, with 25% vesting on April 24, 2027, and the remainder vesting in equal monthly installments over the following 36 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is expected behavior for a publicly traded company.

Positives

• Equity-based compensation aligns the interests of the President with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future performance of the company's common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of an executive equity grant.

Industry Context

StockSavvy.ai notes that executive equity grants are standard practice in the biotechnology sector to incentivize leadership and retain talent, particularly in companies focused on long-term drug development cycles.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 25% of the options on April 24, 2027.
• Continued monthly vesting of the remaining options through April 2030.

Key Dates

Keywords

Inhibrx Biosciences, INBX, Stock Options, Insider Transaction, Executive Compensation